THRX's Business Model
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://theseusrx.com |
| CEO (Chief Executive Officer) | Iain D. Dukes DPHIL, |
| Number of Employees | |
| IPO date | October 7, 2021 |
THRX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 245 Main Street |
| City | Cambridge |
| State | MA |
| Phone | 857 400 9491 |
| Zip Code | 02142 |
| Other Identifiers | |
| CIK | 0001745020 |
| ISIN | US88369M1018 |
| CUSIP | 88369M101 |
| Open | 4.06 |
| Previous Close | 4.06 |
| Volume | 677.7 Thou. |
| Average Volume | 849.6 Thou. |
| Day’s Range | 4.06 – 4.07 |
| 52 Week Range | 2.05-12.37 |
| MA (50) | 3.9506 |
| MA (200) | 4.99585 |
| Market Cap | 181.5 Mil. |
| Shares Out. | 44.65 Mil. |
| Earnings Date | Mar 09, 2024 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
